Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIC Haplo-HSCT for Elderly or High Comorbidity Patients
NCT03412409Phase 2Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Feb 2018
- Primary completion
- Sep 2025
- Modality
- Antibody Conjugates, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of cytarabine, busulfan, cyclophosphamide, fludarabine, semustine in acute leukemia, myelodysplastic syndromes (MDS), sponsored by Peking University People's Hospital. Started Feb 2018; status: recruiting.
02
Drugs
cytarabinebusulfancyclophosphamidefludarabinesemustine
03
Conditions
acute leukemiamyelodysplastic syndromes (MDS)
Beyond the preview
Go deeper on NCT03412409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03412409.